News

Claimed to be the first vaccine against the disease to receive FDA’s marketing approval, IXCHIQ uses Albumedix’ Recombumin. Recombumin is an animal origin-free recombinant human albumin and is

The oral CDK2 inhibitor from Ensem is an investigational new drug (IND) application-ready asset. BeiGene R&D global head Lai Wang said: “We are committed to developing novel molecules

The clinical-stage long-acting human IL-7, NT-I7 is being developed in oncologic and immunologic indications. In these indications, T cell amplification and increased functionality are expected to provide clinical

EBGLYSS is intended for patients aged 12 years and above who are candidates for systemic therapy. The company plans to begin selling the product in Germany initially and

Homology Medicines will issue shares of its common stock to Q32 Bio stockholders as part of the merger deal, in return for cancelling Q32 Bio’s capital stock. Pre-merger

The company has also enrolled the first US patient in a Phase Ib/IIa clinical study to assess XTMAB-16 for the treatment of patients with pulmonary sarcoidosis. Pulmonary sarcoidosis

The first and only FDA-approved ready-to-use oral liquid metronidazole in the country, LIKMEZ is intended for patients who may struggle with dysphagia, difficulty swallowing, or high taste sensitivities.

The company filed the application to manufacture and sell the second-generation oral calcineurin inhibitor, voclosporin, in Japan. In January 2021, voclosporin along with a background immunosuppressive therapy regimen

A clinical stage pipeline asset for the company, LP-310 is intended to be indicated for inflammatory diseases of the oral cavity, including oral lichen planus and oral GvHD.